Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB2 vs Remicade in Rheumatoid Arthritis Despite Methotrexate Therapy
2012-005733-37Phase 3Completed
- Sponsor
- Samsung Bioepis
- Start
- May 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of SB2 in rheumatoid arthritis (RA) (2 arms), sponsored by Samsung Bioepis. Primary endpoint: ACR20 response at Week 30. Started May 2013; status: completed.
02
Drugs
SB2
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-005733-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005733-37.